Press Releases
TEL AVIV, Israel, Feb. 25, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that Dr. Maya Halpern, Galmed's Chief Medical Officer, will present a poster at the 1st European Fatty Liver Conference (EFLC), which will be held in Maastricht (the Netherlands) on March the 5th and 6th 2015. Allen Baharaff, the Company's Chief Executive Officer, will also be in attendance.
One of the goals of the conference is to create awareness of the crucial role the liver plays in the systemic consequences of fatty liver disorders, including Non-Alcoholic Steato-Hepatitis ("NASH"). Dr. Halpern will present the importance of testing endothelial function, or the function of the lining of blood vessels, as an early marker of atherosclerosis, or the hardening of the arteries. "NASH is the manifestation of metabolic syndrome in the liver," commented Dr. Halpern. "NASH patients have not only a high risk of cirrhosis and liver cancer, but also possess a significantly higher risk of heart disease. A drug for the treatment of NASH that also protected against cardiovascular atherosclerotic complications, namely heart attacks and strokes, would be beneficial to the NASH patient population."
Dr. Halpern continued, "in our Phase IIa study, aramchol demonstrated, in a dose-dependent manner, trends of improvement in endothelial function. In addition to liver fat content and histological signs of NASH, our Phase IIb study, ARREST (ARamchol for the REsolution of STeatohepatitis), is examining endothelial function using the validated EndoPAT™ technology developed by Itamar Medical Ltd. Confirmation of aramchol's effect on the improvement of endothelial function, if found, could position aramchol as a highly differentiated option in the treatment of patients with NASH." Mr. Baharaff concluded, "we are proud to provide corporate sponsorship in first EFLC, which is a watershed event in recognizing the importance of fatty liver disorders by the European medical community, and an ideal venue to present to the international key opinion leaders Galmed's differentiated therapeutic strategy."
About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.
Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in the registration statement on Form F-1 (File No. 333 -193792), initially filed with the Securities and Exchange Commission, or the SEC, on February 6, 2014 and declared effective by the SEC on March 12, 2014, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update any forward-looking statements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-present-at-the-european-fatty-liver-conference-300041167.html
SOURCE Galmed Pharmaceuticals Ltd.